| HOME >> BIOLOGY >> TECHNOLOGY |
• However, some firms experience very low failure rates of less than 10% while others report very high failure rates in excess of 70%. Chapter 2
• Many biotech tech transfer failures can be traced to an inability on the part of the sponsor to adequately perform initial due diligence. Chapter 3
• Over the next five years, the role of biotechnology in drug development is expected to expand strongly as biotech drug sales rise by 17.7% per year while small molecule drug sales grow by just 2.9% annually. Chapter 4
Key questions answered
• Why is biotech tech transfer rising so quickly? (Because biotechnologies offer a means to address unmet medical needs and many new technologies have been developed outside of Big Pharma)
• Which types of biotech tech transfer approaches are currently most common? (Licensing and acquisitions)
• Which trends will further boost biotech tech transfer in the future? (Economic recovery, healthcare reform, clarification of biosimilars regulation, rising biotech funding)
• What are the most common reasons for the failure of biotech tech transfers? Deficiencies in due diligence, inappropriate deal structure, differing cultures, inappropriate project organization and expectations and technology failure)
Companies mentioned
Eli Lilly , Ensemble Discovery , Gene Network Sciences , Genentech , GlaxoSmithKline , Horizon Discovery , Merck & Co. , Novartis , Novus Biologicals , Thiakis
Table of Contents
Building Biotech Technology Transfer
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |